June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
HiBiT tagging of endogenously expressed retinal degeneration-associated proteins enables sensitive, unbiased chemical and genetic modulator screens.
Author Affiliations & Notes
  • Sophia DiCesare
    Opthalmology, The University of Texas Southwestern Medical Center, Dallas, Texas, United States
  • Steffi Daniel
    Opthalmology, The University of Texas Southwestern Medical Center, Dallas, Texas, United States
  • Melissa McCoy
    HTS, The University of Texas Southwestern Medical Center, Dallas, Texas, United States
  • Bruce Posner
    HTS, The University of Texas Southwestern Medical Center, Dallas, Texas, United States
  • John Hulleman
    Opthalmology, The University of Texas Southwestern Medical Center, Dallas, Texas, United States
  • Footnotes
    Commercial Relationships   Sophia DiCesare None; Steffi Daniel None; Melissa McCoy None; Bruce Posner None; John Hulleman None
  • Footnotes
    Support  P30 EY030413, Fichtenbaum Charitable Trust, Roger and Dorothy Hirl Research Fund
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3172 – F0446. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sophia DiCesare, Steffi Daniel, Melissa McCoy, Bruce Posner, John Hulleman; HiBiT tagging of endogenously expressed retinal degeneration-associated proteins enables sensitive, unbiased chemical and genetic modulator screens.. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3172 – F0446.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Until now, methods for identifying compounds or genetic manipulations that alter the homeostasis of retinal proteins of interest (POI) have been limited mainly to non-physiologic constitutive overexpression of large fluorescent/luminescent reporter tags fused to that POI. Here we describe an attractive alternative strategy that allows for easy monitoring endogenously expressed POIs from retinal cells for unbiased drug/gene discovery.

Methods : As an initial proof-of-principle, we used a CRISPR/Cas9 ribonucleoprotein and ssODN HDR template to genome engineer immortalized RPE cells to express a 2xFLAG HiBiT tag (29 total residues) on fibulin-3 (F3, EFEMP1), a protein associated with Malattia Leventinese/Doyne Honeycomb Retinal Dystrophy and glaucoma. To detect the HiBiT tag, conditioned media or lysates were supplemented with LgBiT and substrate to generate NanoBiT (HiBiT + LgBiT), a bright and stable luciferase. Cells were used to efficiently screen ~10,000 compounds from the UT Southwestern chemical library. Toxic compounds and NanoBiT inhibitors were identified in counterscreens. Hit compounds were verified in dose-response, repurchased, and validated in differentiated/polarized primary porcine RPE cells to confirm their activity on F3 secretion/intracellular levels.

Results : Genome engineering of F3 resulted in the formation of a single 2xFLAG-tagged HiBiT species as detected by western blotting. LgBiT complementation of 2xFLAG HiBiT F3 in media enabled detection in sub-microliter volumes. Compound screening identified both F3 enhancers and reducers. Surprisingly, a series of drugs typically used for treatment of glaucoma significantly increased F3 expression whereas a set of compounds that can regulate epithelial to mesenchymal transition (EMT) signaling significantly reduced both secreted and intracellular F3.

Conclusions : These findings support the use of the versatile 2xFLAG HiBiT tag in retinal drug discovery. Such an approach can also be used to enrich (via the 2xFLAG peptide) endogenous POI interacting partners. We speculate that this same general approach can also be applied to other retinal degeneration genes and may ultimately be useful in identifying mutant-specific drugs or genetic manipulators.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×